Cellectar Biosciences, Inc.

Our Clinical Studies

Iopofosine Clinical Studies

We are currently enrolling patients with Waldenstrom’s macroglobulinemia (WM) in a CLOVER-WaM pivotal study utilizing iopofosine. Iopofosine is also being evaluated in a multi cohort CLOVER-1 Phase 2 study in adult B-cell malignancies and the CLOVER-2 Phase 1 study for a variety of pediatric cancers.

Additionally, we are currently collaborating with BBK Worldwide to provide new concierge services for patients participating in some of Cellectar's current clinical studies. To learn more about how both Cellectar and BBK Worldwide are working to improve the patient experience, click here.

Clinical Studies Are Key To Finding New and Better Treatments
Clinical studies are a fundamental necessity in the development and advancement of new treatment options for battling cancer, and you may not know it, but you could play an important role. Clinical studies need patients to enroll in them so that they can advance through the processes necessary to potentially get a new treatment to market. Your participation in clinical studies may help create a better treatment landscape for future cancer patients.

To learn more general information about clinical studies, please visit www.cancer.org and find the "Clinical Studies" section.

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.

Status

Recruiting

View Clinical Study

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

Status

Active, not recruiting

View Clinical Study

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.

Status

Completed

View Clinical Study

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.

Status

Recruiting

View Clinical Study

Enrollment

For more information on enrollment into our current clinical studies, please contact us or visit clinicaltrials.gov for location information.

Contact Us Visit ClinicalTrials.gov

Expanded Access Policy

Learn More